Evidence map›Paper›PMID 27553379›Full record

ArticleAnnals of hematology2016

The impact of H63D HFE gene carriage on hemoglobin and iron status in children.

Kaczorowska-Hac Barbara, Luszczyk Marcin, Antosiewicz Jedrzej, Ziolkowski Wieslaw, Adamkiewicz-Drozynska Elzbieta, Mysliwiec Malgorzata, Milosz Ewa, Kaczor Jan Jacek

Open access · hybridAbstract read
In one paragraph

Article in Annals of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Interactive Effects between Chronic Lead Exposure and the Homeostatic Iron Regulator TransportInternational journal of environmental research and public health · 2019
    Article
  6. [Hfeprotein impact on iron metabolism].Developmental period medicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaczorowska-Hac BarbaraDepartment of Occupational Therapy, Gdansk University of Physical Education and Sport, K Gorski 1 Str., 80-336, Gdansk, Poland. barbara.kaczorowska@awf.gda.pl.
Luszczyk MarcinDepartment of Physiology, Gdansk University of Physical Education and Sport, Gdansk, Poland.
Antosiewicz JedrzejDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, Poland.
Ziolkowski WieslawDepartment of Bioenergetics and Nutrition, Gdansk University of Physical Education and Sport, Gdansk, Poland.
Adamkiewicz-Drozynska ElzbietaDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
Mysliwiec MalgorzataDepartment of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland.
Milosz EwaLaboratory of Molecular Biology at the Medical University of Gdansk, Gdansk, Poland.
Kaczor Jan JacekDepartment of Physiotherapy, Gdansk University of Physical Education and Sport, Gdansk, Poland.
Gdańsk Medical University · PLGdansk University of Physical Education and Sport · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular mechanism that regulates iron homeostasis is based on a network of signals, which reflect on the iron requirements of the body. Hereditary hemochromatosis is a heterogenic metabolic syndrome which is due to unchecked transfer of iron into the bloodstream and its toxic effects on parenchymatous organs. It is caused by the mutation of genes that encode proteins that help hepcidin to monitor serum iron. These proteins include the human hemochromatosis protein -HFE, transferrin-receptor 2, hemojuvelin in rare instances, and ferroportin. HFE-related hemochromatosis is the most frequent form of the disease. Interestingly, the low penetrance of polymorphic HFE genes results in rare clinical presentation of the disease, predominantly in middle-aged males. Taking into account the wide dispersion of HFE mutation in our population and also its unknown role in heterozygotes, we analyzed the impact of H63D HFE carriage in the developmental age, with respect to gender, on the iron status and hemoglobin concentration of carriers in comparison to those of wild-type HFE gene (12.7 ± 3.07 years, 42 boys and 41 girls). H63D carriers presented higher blood iron, transferrin saturation, and ferritin concentration than wild-type probands (p < 0.05.) Interestingly, male H63D carriers showed higher hemoglobin concentration than the unburdened children. Moreover, in the H63D carrier group, a positive correlation between iron and hemoglobin was noted. In conclusion, this study demonstrates that changes in iron metabolism occur at a young age in HFE heterozygotes.

Indexed as

HeterozygoteAdolescentChildFemaleGenetic VariationHemochromatosis ProteinHemoglobinsHumansIronMaleHemochromatosis ProteinHemoglobinsHFE protein, humanIronChildrenFerritinHemoglobinHFE mutationIronTransferrin saturation

Identifiers

PMID27553379
PMCPMC5093215
OpenAlexW2513112632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.